Airgas, Inc. (NYSE: ARG), one of the nation’s leading suppliers of
industrial, medical, and specialty gases, and related products, today
announced that it will release its fiscal 2015 third quarter earnings
before the market opens on Tuesday, February 3, 2015, and will host a
teleconference at 10:00 a.m. ET that same day.
PROS Holdings, Inc. (NYSE: PRO), a big data software company, today
announced that Chief Operating Officer Blair Crump and Chief Strategy
Girgenti will present at the Needham Growth Conference in New York
Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) ("Kulicke & Soffa",
"K&S" or the " Company") today announced
the launch of the Quantis TM QFN Capillary, a copper wire
bonding capillary based on the Company’s latest and most advanced
ceramics composite platform, for improved wear resistance, extended life
span and superior bonding quality.
Qlik, (NASDAQ: QLIK), a leader in data discovery, today announced it
will report its fourth quarter and full year 2014 financial results
after the U.S. financial markets close on Thursday, February 12, 2015.
The Medicines Company (NASDAQ:MDCO) (the “Company”) today announced that
it proposes to offer $300 million aggregate principal amount of its
convertible senior notes due 2022, subject to market conditions and
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company
focused on the discovery and development of biased ligands targeting G
protein coupled receptors (GPCRs), today announced the initiation of a
Phase 2b clinical trial of TRV130 for acute postoperative pain in
patients following abdominoplasty surgery.
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it
will webcast its corporate presentation at the 33 rd Annual
J.P. Morgan Healthcare Conference on Monday, January 12 at 12:30 p.m. ET
(9:30 a.m. PT). The audio portion of management’s remarks may be
accessed live through Vertex’s website at www.vrtx.com
in the “Investors” section under the “Events and Presentations” page.
OvaScience SM (NASDAQ: OVAS), a global life sciences company
focused on the discovery, development and commercialization of new
fertility treatments, announced today it has commenced an underwritten
public offering of up to $85 million of shares of its common stock.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.